Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Drug Name | Naxitamab |
Trade Name | Danyelza |
Synonyms | hu3F8 |
Drug Descriptions |
Danyelza (naxitamab) is an antibody that targets the ganglioside GD2, potentially resulting in increased anti-tumor immune response against GD2-expressing tumor cells (PMID: 22754766). Danyelza (naxitamab) is FDA approved for use in combination with GM-CSF in pediatric patients one year of age and older and adult patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow who achieved a partial response, minor response, or stable disease to prior therapy (FDA.gov). |
DrugClasses | |
CAS Registry Number | 1879925-92-4 |
NCIT ID | C123428 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Aldesleukin + Cyclophosphamide + Naxitamab | Aldesleukin Cyclophosphamide Naxitamab | 0 | 1 |
Ceritinib + Naxitamab | Ceritinib Naxitamab | 0 | 1 |
Irinotecan + Naxitamab + Sargramostim + Temozolomide | Irinotecan Naxitamab Sargramostim Temozolomide | 0 | 2 |
Isotretinoin + Naxitamab + Sargramostim | Isotretinoin Naxitamab Sargramostim | 0 | 1 |
Naxitamab | Naxitamab | 0 | 1 |
Naxitamab + Sargramostim | Naxitamab Sargramostim | 0 | 3 |